ViiV HEALTHCARE RANKED #1 FOR THE TENTH SUCCESSIVE YEAR IN PATIENTVIEW’S ‘CORPORATE REPUTATION OF PHARMA – FROM THE PATIENT PERSPECTIVE 2022 - 2023’ SURVEY
ViiV Healthcare ranked #1 for tenth consecutive year in PatientView’s ‘Corporate Reputation of Pharma’ survey
We are delighted to be ranked as the number one pharmaceutical company for the tenth consecutive year in PatientView’s ‘Corporate Reputation of Pharma – from the ‘Patient Perspective 2022 - 2023’ survey – as assessed by patient groups working with our company. For patient organisations 'familiar' with us, we ranked second overall. The PatientView research is based on feedback from the patient group community across the world.
We are committed to living our mission to leave no person living with HIV behind – this means listening to the community, understanding their needs and working together to fight HIV and HIV-related stigma. We are grateful for the close collaboration and support of HIV-related patient groups in advancing the dialogue and ensuring that HIV remains a health priority around the world.
In 2022 we celebrated the 30th year of Positive Action, the longest-running corporate programme designed to support diverse communities most affected by HIV globally. Our ‘Positive Action at 30’ campaign allowed us to reflect on three decades of success, only made possible through community collaboration, while also looking forward to what we can jointly achieve in the future.
The importance of listening to the HIV community and addressing their evolving needs has been illustrated most recently by the tragic events in Ukraine. ViiV has provided over £850,000 to date, to support 11 community-based organisations with humanitarian response efforts, both across Ukraine and in surrounding countries hosting refugees.
There is much work still to do, but together we will end HIV. Until then, we continue to work towards both improving and saving lives. With our community partners, we will continue to challenge HIV-related stigma and discrimination.
Finally, we would like to thank everyone who took the time to participate and share their views in the survey, which we will continue to use to keep us accountable to our mission. We look forward to continuing our collaboration with you.
Harmony P, Garges, Chief Medical Officer, ViiV Healthcare
NP-GBL-HVX-COCO-230009
Media contacts
For our corporate press office, email: Rachel Jaikaran
OR call +44 7823 523 755
For US-specific media enquiries, email: Audrey Abernathy
OR call +1 919 605 4521
If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the GSK Reporting Tool link https://gsk.public.reportum.com/. By reporting side effects, you can help provide more information on the safety of this medicine.
If you are from outside the UK, you can report adverse events to GSK/ ViiV by selecting your region and market, here.
